Udry Sebastián, Latino José O, Perez Stephanie Morales, Belizna Cristina, Aranda Federico, Esteve-Valverde Enrique, Wingeyer Silvia Perés, Romero Diego S Fernández, Alijotas-Reig Jaume, de Larrañaga Gabriela
Research Center "Fundación Respirar", Av. Cabildo 1548, C1426AEN, City of Buenos Aires, Argentina.
Autoimmune Thrombophilic Diseases and Pregnancy Section, Acute Hospital "Dr. Carlos G. Durand", Av. DíazVélez 5044, C1405AEN, City of Buenos Aires, Argentina.
Clin Rheumatol. 2024 May;43(5):1615-1622. doi: 10.1007/s10067-023-06846-8. Epub 2024 Mar 4.
(I) To identify and measure the clinical consequences of a delayed diagnosis in patients with primary obstetric antiphospholipid syndrome (POAPS), in terms of time and events associated to antiphospholipid syndrome (APS), and (II) to evaluate the impact of their treatment status on perinatal outcomes, before and after diagnosis.
This retrospective multicentre study included 99 POAPS women who were separated in two groups of timelines based on their diagnostic status: group 1: women who met the clinical criteria for POAPS; group 2: included the same patients from group 1 since they meet the laboratory criteria for APS. In group 1, we assessed the following variables: obstetric events, thrombotic events and time (years) to diagnosis of APS. We also compared perinatal outcomes between patients in group 1 vs. group 2. Women in group 2 were treated with standard of care for POAPS. Simple and multivariable logistic regression analyses were performed.
Regarding the impact of the delay on diagnosis, a total of 87 APS-related events were recorded: 46 miscarriages, 32 foetal losses and 9 premature deliveries before the 34th week due to preeclampsia, and one thrombosis. The estimated rate of preventable events was 20.58 per year/100 patients. The mean diagnostic delay time was 4.27 years. When we compared both groups during pregnancy, we found that patients in group 1 (no treatment) had a higher association with pregnancy losses [OR = 6.71 (95% CI: 3.59-12.55), p < 0.0001].
Our findings emphasize the negative impact of POAPS underdiagnosis on patient health and the critical importance of a timely intervention to improve pregnancy outcomes. Key Points •Our study shows the relevance of underdiagnosis on primary obstetric antiphospholipid syndrome (POAPS). •These patients presented a high risk of APS-related events with each passing year. •Shorter diagnostic delay time was observed in the reference centres.
(I)从时间以及与抗磷脂综合征(APS)相关的事件方面,识别并衡量原发性产科抗磷脂综合征(POAPS)患者延迟诊断的临床后果;(II)评估诊断前后其治疗状态对围产期结局的影响。
这项回顾性多中心研究纳入了99名POAPS女性,根据她们的诊断状态分为两组时间线:第1组:符合POAPS临床标准的女性;第2组:包括第1组中的相同患者,因为她们符合APS的实验室标准。在第1组中,我们评估了以下变量:产科事件、血栓形成事件以及诊断APS的时间(年)。我们还比较了第1组与第2组患者的围产期结局。第2组中的女性接受POAPS的标准治疗。进行了单因素和多因素逻辑回归分析。
关于延迟诊断的影响,共记录了87起与APS相关的事件:46次流产、32次胎儿丢失以及9次因先兆子痫在孕34周前早产,并发生1次血栓形成。可预防事件的估计发生率为每年20.58/100例患者。平均诊断延迟时间为4.27年。当我们在孕期比较两组时,发现第1组(未治疗)的患者与妊娠丢失的关联更高[比值比(OR)=6.71(95%置信区间:3.59 - 12.55),p < 0.0001]。
我们的研究结果强调了POAPS诊断不足对患者健康的负面影响以及及时干预以改善妊娠结局的至关重要性。要点 •我们的研究表明原发性产科抗磷脂综合征(POAPS)诊断不足的相关性。•这些患者每年发生与APS相关事件的风险很高。•在参考中心观察到诊断延迟时间较短。